GlobalData on MSN20h
GSK eyes up combo approval for previously withdrawn myeloma drug
The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
Pharmabiz6h
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
The Pharma Letter16h
FDA signals progress on the western front for belantamab mafodotin
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab ...
GSK's Blenrep treatment accepted for review by FDA
Pharma titan GSK has announced that US regulators have accepted for review Blenrep combinations for the treatment of relapsed ...
GSK’s Blenrep Nears FDA Review for Myeloma
GlaxoSmithKline (GB:GSK) has released an update.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium - Now ...
STAT18h
What to make of Trump’s health care nominees
The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...
BioLineRx Reports Strategic Moves in Q3 2024
Bioline RX Ltd Sponsored ADR ( (BLRX) ) has released its Q3 earnings. Here is a breakdown of the information Bioline RX Ltd Sponsored ADR ...
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
Acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across ...
Wausau Daily Herald on MSN7m
'He didn't want a traditional funeral’: Celebrating Dan O'Connell; Bob Gawlitta walks away
Former Wisconsin Rapids Lincoln baseball assistant Dan O'Connell recently lost an 18-year battle with leukemia. Here is how ...
BioLineRx (NASDAQ:BLRX) Given New $9.00 Price Target at HC Wainwright
BioLineRx (NASDAQ:BLRX – Free Report) had its target price trimmed by HC Wainwright from $21.00 to $9.00 in a report issued on Monday morning,Benzinga reports. The firm currently has a buy rating on ...
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) ("Poseida"), a clinical-stage allogeneic cell therapy and genetic medicines company ...
Lehigh Valley Topper Cancer Institute announces new treatment option
The Lehigh Valley Topper Cancer institute has announced that it is now offering treatment using autologous chimeric antigen ...